Chemical Component Summary

Name7-[4-[4-[2,3-bis(chloranyl)phenyl]piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one
Identifiers7-[4-[4-[2,3-bis(chloranyl)phenyl]piperazin-1-yl]butoxy]-3,4-dihydro-1~{H}-quinolin-2-one
FormulaC23 H27 Cl2 N3 O2
Molecular Weight448.38
TypeNON-POLYMER
Isomeric SMILESClc1cccc(N2CCN(CCCCOc3ccc4CCC(=O)Nc4c3)CC2)c1Cl
InChIInChI=1S/C23H27Cl2N3O2/c24-19-4-3-5-21(23(19)25)28-13-11-27(12-14-28)10-1-2-15-30-18-8-6-17-7-9-22(29)26-20(17)16-18/h3-6,8,16H,1-2,7,9-15H2,(H,26,29)
InChIKeyCEUORZQYGODEFX-UHFFFAOYSA-N

Chemical Details

Formal Charge0
Atom Count57
Chiral Atom Count0
Bond Count60
Aromatic Bond Count12

Drug Info: DrugBank

DrugBank IDDB01238 
NameAripiprazole
Groups
  • approved
  • investigational
DescriptionAripiprazole is an atypical antipsychotic orally indicated for treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's[Label]. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania[Label]. Aripiprazole exerts its effects through agonism of dopaminic and 5-HT1A receptors and antagonism of alpha adrenergic and 5-HT2A receptors[Label,A4393]. Aripiprazole was given FDA approval on November 15, 2002[L6136].
Synonyms
  • Aripiprazolum
  • Aripiprazol
  • Aripiprazole
Brand Names
  • Sandoz Aripiprazole
  • Abilify MyCite
  • Aripiprazole
  • Abilify Maintena
  • Aripiprazole Mylan Pharma
IndicationAripiprazole is indicated for manic and mixed episodes associated with bipolar I disorder, irritability associated with autism spectrum disorder, treatment of schizophrenia, treatment of Tourette's disorder, and as an adjunctive treatment of major depressive disorder[Label]. An injectable formulation of aripiprazole is indicated for agitation associated with schizophrenia or bipolar mania[Label].
Categories
  • Adrenergic alpha-1 Receptor Antagonists
  • Adrenergic alpha-Antagonists
  • Adrenergic Antagonists
  • Agents producing tachycardia
  • Agents that produce hypertension
ATC-CodeN05AX12
CAS number129722-12-9

Drug Targets

NameTarget SequencePharmacological ActionActions
5-hydroxytryptamine receptor 1AMDVLSPGQGNNTTSPPAPFETGGNTTGISDVTVSYQVITSLLLGTLIFCA...unknownpartial agonist
Dopamine D2 receptorMDPLNLSWYDDDLERQNWSRPFNGSDGKADRPHYNYYATLLTLLIAVIVF...unknownantagonist,partial agonist
5-hydroxytryptamine receptor 2AMDILCEENTSLSSTTNSLMQLNDDTRLYSNDFNSGEANTSDAFNWTVDSE...unknownantagonist,partial agonist
Alpha-1A adrenergic receptorMVFLSGNASDSSNCTQPPAPVNISKAILLGVILGGLILFGVLGNILVILS...unknownantagonist
Alpha-1B adrenergic receptorMNPDLDTGHNTSAPAHWGELKNANFTGPNQTSSNSTLPQLDITRAISVGL...unknownantagonist
View More
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
PubChem60795
ChEBICHEBI:31236
ChEMBLCHEMBL1112
PharosCHEMBL1112